Wall Street

    25291 POSTS

    Exclusive articles:

    2 Retirement Stocks to Buy for 2024

    As investors transition to a new year, many may be adding cash to traditional or Roth IRA plans. Often, such contributions find their way...

    The Future of Electric Vehicles: What to Expect in the Next Decade

    Electric vehicles have gone from niche to mainstream over the past decade, and investors have expectations for even more growth in the next decade....

    AbbVie’s Recent ImmunoGen Acquisition Looks Brilliant: Here’s Why

    Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings. When it...

    Should Investors Buy the Dip in UiPath Stock for 2024?

    Fool.com contributor Parkev Tatevosian evaluates UiPath (PATH 1.22%) stock and lets growth stock investors know if they should add it to their portfolios for...

    1 Grim Tiding and 2 Silver Linings for Canopy Growth Stock in 2024

    Recognizing the positives that are present in a generally negative situation is a key skill in investing and in life. It's also a skill...

    Breaking

    What Drives Europe’s Markets? A Deep Dive with Euronext

    Discover the engine behind Europe’s financial markets in this...

    2025 is off to a bumpy start. A sign of things to come?

    Market recap Equity markets slumped this week and have faced...

    In Case You Missed It! Backtesting in Trading

    Your Privacy When you visit any website it may use...

    2,700 Calls Trade in Royal Pharma plc (Symbol: RPRX)

    Your Privacy When you visit any website it may use...